Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report.

ABSTRACT: The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient's symptoms and improved his quality of life.

SUBMITTER: Chen J 

PROVIDER: S-EPMC7683926 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature